<div data-server-rendered="true" id="__nuxt"><div id="__layout"><div class="outer-container"><div class="content-container"> <div class="answer_container" style="min-height:calc(100vh - 54px);" data-v-0eba195e=""><div class="content_outer_container" data-v-0eba195e=""><div class="share_preview_container" data-v-0eba195e=""><div class="dialog_list" data-v-0eba195e=""><div class="dialog_item" data-v-0eba195e=""><div class="dialog_question fir_dialog_question" data-v-0eba195e=""><div class="question_con" data-v-0eba195e=""><h1 class="fir_question_content" data-v-0eba195e="">
                                    How did INO's operating expenses trend in Q4 2024?
                                </h1> <div class="user_slot" data-v-0eba195e=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/default_aime_user.ec532c9.png" alt="user" class="avatar" data-v-0eba195e=""> <span class="user_desction" data-v-0eba195e="">
                                        
                                        5/8/2025 07:23pm
                                    </span></div></div></div> <div class="seo-text-answer" data-v-0eba195e="">In Q4 2024, INO's operating expenses were not available. However, the latest available data is from Q3 2024, where the company reported research and development expenses of $18.73 million, compared to $15.50 million in Q3 2023. This indicates a trend of increasing operating expenses over the period from Q3 2023 to Q3 2024, but specific Q4 2024 data is not currently available.</div> <div class="dialog_answer" data-v-0eba195e=""><div class="dialog_content" data-v-0eba195e=""><div class="answer_content" data-v-0eba195e=""></div></div></div></div></div> </div></div></div> </div> <div class="extra-module" data-v-261d488f=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/recommend-logo.4f9ccc8.png" alt="right-logo" fetchpriority="high" class="recommend-logo-img" data-v-261d488f=""> <div class="recommend-part" data-v-7790c618="" data-v-261d488f=""><div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/screener-recommend-icon.b007ca8.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime finds your next big stock</span></div> </div> <div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/stock-recommend-icon.77f1c78.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime powers your decisions</span></div> </div></div> </div> <div class="container-mask" style="display:none;"></div></div></div></div><script>window.__NUXT__=(function(a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,A,B,C,D,E,F,G,H,I,J,K,L,M,N,O,P,Q,R,S,T,U,V,W,X,Y,Z,_,$,aa,ab,ac,ad,ae,af,ag,ah,ai,aj,ak,al){return {layout:"default",data:[{noData:c,currentQuestion:d,textDescription:D,comeFrom:"AInvestShareLink",events:[],answerSource:h}],fetch:{},error:i,state:{sharePreviewModule:{loadJgySuccess:j,dialogRenderList:[{originAnswer:{input_media_info:[],session_round:1,agent_id:a,output_media_info:[],task_id:a,language:a,source:h,cache_builder:a,reply_action:"Answer",execute_mode:u,event_refresh_answer:a,param:"{\"entity_info\":{},\"add_info\":{\"ori_question\":\"How did INO's operating expenses trend in Q4 2024?\"},\"event_list\":[],\"client_ip\":\"\",\"question\":\"How did INO's operating expenses trend in Q4 2024?\",\"user_id\":\"dp23140486\",\"user_name\":\"\",\"trace_id\":\"521d02bf-13de-4bd3-999c-deec4b682248\",\"session_id\":\"521d02bf-13de-4bd3-999c-deec4b682248\",\"source\":\"ths_ainvest_lite_web\",\"input_type\":\"typewrite\"}",agent_info:[{info_type:"search",raw_data:{number:E,title:F,summary:G,full_summary:"New immunology data for INO-3107 supporting proposed mechanism of action presented at several recent conferences Data showed ability of INO-3107 to induce an antigen-specific cytotoxic T cell response against HPV-6 and HPV-11 and drive recruitment of T cells into airway tissues and papilloma Data showed INO-3107 induced expansion of new clonal T cells that infiltrate airway tissues and correspond with reduction of surgeries for RRP patients observed in Phase 1\u002F2 trial Continued progress on preparing regulatory submissions for INO-3107 All non-device BLA modules on track for completion by end of 2024 BLA submission remains targeted for mid-2025 PLYMOUTH MEETING, Pa., Nov. 14, 2024 \u002FPRNewswire\u002F -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the third quarter of 2024 and provided an update on recent company developments. \"We continue to be focused on advancing INO-3107 and delivering a non-surgical option to RRP patients. Toward this goal, we expect to have all non-device modules for our BLA completed by year end, while in parallel we continue to implement the plan to resolve the previously announced manufacturing issue with the single-use array component of the device. With this progress, we continue to target the submission of our BLA in mid-2025,\" said Dr. Jacqueline Shea, INOVIO's President and Chief Executive Officer. \"Our development of INO-3107 is supported by a growing body of research that collectively points to INO-3107's potential to be an important therapeutic option for all RRP patients regardless of the severity of their disease. We recently presented new immunology data highlighting the ability of INO-3107 to induce new populations of T cells that travel to the airway tissue and papilloma and correspond with clinical benefit. We've also presented our full safety an",url:H,image_url:a,video_url:a,publish_time:I,search_extra_info:{search_burial_info:{id:v,uid:J,ab:{scene_id:K,layer_exp:[{layer_id:L,exp_id:M}]}}},simhash:"27683807681e3082",msg_id:v}}],answer_chain_name:N,agent_mode:O,native_answer:a,come_from:a,text_answer:D,trace_id:e,cost:12396,event_names:a,question:d,fallback_type:P,input_type:Q,fall_back_reason:{fall_back_type:P,may_fall_back_reason:"UNKNOWN",risk_detail:{matched_words:[]}},session_id:e,first_return_cost:2135,cache_type:"no_cache",question_id:e,transfer_question:d,signal_type:"ON_COMPLETE",start_time:w,remote_svc:h,slots:[],answer_type:u,user_id:r,skill_name:x},renderList:[{type:"base_info",answer_path:"logs\u002FbaseInfo",logs:[],base_info:{trace_id:e,session_id:e,user_id:r,question:d,source:h,raw_question:d,version:"3.4.1",action_name:x,nlu:{entity:[{type:R,value:"INO.O",market:S}]},output_time:w,deep_research:c,deep_thinking:c,agent_mode:O},extra:{}},{answer_path:k,section:{id:l,info_texts:["Thinking"],show_type:m,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"begin"},logs:[],extra:{is_deep_research:c,deep_thinking:c}},{answer_path:k,section:{id:l,info_texts:["Querying Stock: INO Operating Expenses in Q4 2024"],show_type:m,choice:[],result_page:{},tag_info_list:[],is_last:b,status:T},logs:[],extra:{action:"Querying Stock",action_input:"INO Operating Expenses in Q4 2024",thought:"The user seeks to analyze INO's Q4 2024 operating expenses. I should focus on INO's Q4 2024 operating expenses data. I will use FinQuery for the data mentioned above."}},{answer_path:f,section:{id:y,info_texts:[],show_type:s,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:k,section:{id:l,info_texts:["Searching Web: Inovio Pharmaceuticals Operating Expenses Q4 2024"],show_type:m,choice:[],result_page:{},tag_info_list:[],is_last:b,status:T},logs:[],extra:{action:"Searching Web",action_input:"Inovio Pharmaceuticals Operating Expenses Q4 2024",thought:"I am unable to obtain INO's Q4 2024 operating expenses using FinQuery, now I will try again using Search."}},{answer_path:f,section:{id:y,info_texts:[],show_type:s,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:f,section:{id:y,info_texts:[],show_type:s,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:k,section:{id:l,info_texts:["Generating Answer"],show_type:m,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"ongoing"},logs:[],extra:{}},{answer_path:f,section:{id:z,info_texts:[],show_type:A,voice_txt:"In",text_answer:U,rich_text:U,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:f,section:{id:2000,info_texts:[],show_type:A,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[{url:H,image_url:a,video_url:a,title:F,summary:G,index:E,publish_time:I,search_id:v,search_uid:J,search_ab:{scene_id:K,layer_exp:[{layer_id:L,exp_id:M}]},jump_type:"normal"}],is_last:b},logs:[],extra:{}},{answer_path:f,section:{id:z,info_texts:[],show_type:A,voice_txt:". This",text_answer:V,rich_text:V,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"extraInfo\u002FsourceLink",logs:[],extra:{span_id:a,link_id:a,source:a,link_text:a,link_param:a,link_ids:[]}},{answer_path:f,section:{id:1001,info_texts:[],show_type:"fenshi",choice:[],result_page:{},tag_info_list:[{stock_info:{code:W,market_id:S,name:"Inovio Pharmaceuticals",domain:R},pos:12,section_id:z,txt:W,jump_type:"pos_fenshi"}],is_last:b},logs:[],extra:{}},{answer_path:k,section:{id:l,info_texts:["Completed"],show_type:m,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"end"},logs:[],extra:{}},{answer_path:"suggest\u002Fquestions",section:{id:10002,info_texts:[],show_type:"result_page",choice:[{display_text:n,query_text:n,trace_info:{item_id:"5c65508cee19584487d118d0ab0f990e",item_type:g,item_name:n,rec_info:X}},{display_text:o,query_text:o,trace_info:{item_id:"01171570aaf5ff46ee89bebbca882fb5",item_type:g,item_name:o,rec_info:Y}},{display_text:p,query_text:p,trace_info:{item_id:"18a18b69a66cd442d22585f2a413e5bf",item_type:g,item_name:p,rec_info:Z}}],result_page:{components:[{show_type:"lowcode",title_config:{show_type:"title1",data:{h1:a,h2:a},config:{display:c,txt_style:j,type:"1",display2:c,url:a}},request_config:[{source_type:_,related_name:$}],puuid:B,tag:a,category:"custom",uuid:aa}],global:{urp_static_data:[{name:$,value:{status_code:j,columns:[{type:q,index_name:ab,key:ab},{type:q,index_name:ac,key:ac},{type:q,index_name:ad,key:ad},{type:q,index_name:ae,key:ae},{type:q,index_name:af,key:af}],datas:[{send_text:n,item_type:g,rec_info:X,display_text:n,rec_reason:a},{send_text:o,item_type:g,rec_info:Y,display_text:o,rec_reason:a},{send_text:p,item_type:g,rec_info:Z,display_text:p,rec_reason:a}],dataSize:_,status_msg:a}}],lowcode_type:"shunda",interface_request_list:[],lowcode_json:{stack:c,visible:b,childLimit:9999,label:ag,type:"thslc\u002Fthslc-common-container",leaf:c,animate:[],version:"1.0.1",script:[],props:[],path:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fkernel-thslc-resource\u002Fresource\u002Fainvest\u002F0Ae514cfA4\u002Fjs\u002F_thslc-common-container_1.0.1_index.js",isTransparent:b,style:{"background-color":a,"box-shadow":"0px 0px 0px",color:a,width:t,"min-height":"100%",position:ah,height:t},isMaterial:c,id:ag,needTheme:c,hasEditor:c,packed:c,events:[],child:[{readmeUrl:"https:",stack:c,visible:b,customStyle:a,childLimit:j,label:"路径推荐",type:"iwencai\u002FrecommendList",leaf:b,version:"1.12.0",animate:[],url:C,componentUuid:aa,script:[{name:ai,id:20240320,content:"return {\r\n  created: function created() {\r\n    this.isActive = !Boolean(this.$parent.$parent.$parent.$parent.$parent.$parent.question);\r\n    var showId ='tkPanel_bottomTag';\r\n  this.buryPointId = showId;\r\n  }\r\n};"}],props:{recommendList:[],isTransparent:b,renderType:"blue"},path:C,meta:{custom_editor_url:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0editor.js",js_url:C},style:{"background-color":a,margin:"-12px 0px -12px 0px",color:a,display:"block",width:t,position:ah,height:t},isMaterial:b,_id:19,id:ai,hasEditor:b,packed:c,events:[],isSetDefaultValue:b}]}},page:{layout:{layout_data:"[{\"uuid\":\"ztxxx06c0a024223920bbbeb1e0926\",\"showType\":\"lowcode\",\"children\":[]}]"},render_for:aj,voice_txt:a,tracking_info:{},uuid:B},order:{is_auto:c,render_for:aj,chart_type:"command",puuid:B}},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"suggest\u002Finputs",section:{id:10000,info_texts:[],show_type:"choice",choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"logs\u002Ftrace_debug",section:{id:1003,info_texts:[],show_type:s,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{action_name:x,with_paid_index:c,no_refresh_answer:c,answer_source:{agent_id:a,agent_name:a,execute_mode:u,answer_chain_name:N},is_deep_research:c,deep_thinking:c,create_time:1746703427578},is_last:b}],questionItem:{data:{qStr:d,encodeFlag:c,imageData:i,docsData:[],quoteData:i},tplType:"question"},events:ak,agentId:a,param:{entity_info:{},add_info:{ori_question:d},event_list:ak,client_ip:a,question:d,user_id:r,user_name:a,trace_id:e,session_id:e,source:h,input_type:Q}}],userId:r,userName:a,startTime:w,mobileType:a,comeFrom:a,textConstants:{},dialogContainer:i,endSignal:c,theme:"white",showTracePopup:c,traceListData:[],chatTraceTargetIndex:j,traceTableData:i,showMask:c}},serverRendered:b,routePath:"\u002Faime\u002Fshare\u002Fhow-did-inos-operating-expenses-trend-in-q4-2024-4565e5\u002F",config:{_app:{basePath:al,assetsPath:al,cdnURL:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fiwc-aime-seo\u002F"}}}}("",true,false,"How did INO's operating expenses trend in Q4 2024?","521d02bf-13de-4bd3-999c-deec4b682248","other\u002FopenAnswer","llm_generated","ths_ainvest_lite_web",null,0,"progress\u002Fsearching_for",1000,"searching_for","How did INO's operating expenses impact its overall profitability in Q4 2024?","What were INO's total operating expenses in Q4 2024?","Did INO's operating expenses exceed analyst expectations in Q4 2024?","STR","dp23140486","signal","auto","agent","88d65e796e99c6ca_7",1746703415182,"review stocks",999,2001,"rich_text","39196","\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0index.js","In Q4 2024, INO's operating expenses were not available. However, the latest available data is from Q3 2024, where the company reported research and development expenses of $18.73 million, compared to $15.50 million in Q3 2023. This indicates a trend of increasing operating expenses over the period from Q3 2023 to Q3 2024, but specific Q4 2024 data is not currently available.",2,"INOVIO Reports Third Quarter 2024 Financial Results and Recent Business Highlights","CONSOLIDATED STATEMENTS OF OPERATIONS     Three Months Ended September 30, Nine Months Ended September 30,   2024 2023 2024 2023    Revenue from collaborative arrangements and other contracts $— $388,446 $100,762 $729,359  Operating expenses:  Research and development 18,733,584 15,503,032 62,734,89...","https:\u002F\u002Fwww.prnewswire.com\u002Fnews-releases\u002Finovio-reports-third-quarter-2024-financial-results-and-recent-business-highlights-302306267.html","2024-11-14","88d65e796e99c6ca","oeqxkhszf","oeqxkhszf_layer","base","agent_common_v2\nagent-summary","normal_agent","NONE","typewrite","stock","186","thinking","In Q4 2024, INO's operating expenses were not available. However, the latest available data is from Q3 2024, where the company reported research and development expenses of $18.73 million, compared to $15.50 million in Q3 2023[^2]",". This indicates a trend of increasing operating expenses over the period from Q3 2023 to Q3 2024, but specific Q4 2024 data is not currently available.","INO","2+679_496_21_554+0+0+521d02bf-13de-4bd3-999c-deec4b682248+5c65508cee19584487d118d0ab0f990e+llm_generated+aimeTagAnalysis+0+0.0446627177298069+1","2+679_496_21_554+0+0+521d02bf-13de-4bd3-999c-deec4b682248+01171570aaf5ff46ee89bebbca882fb5+llm_generated+aimeTagAnalysis+0+0.03937168046832085+2","2+679_496_21_554+0+0+521d02bf-13de-4bd3-999c-deec4b682248+18a18b69a66cd442d22585f2a413e5bf+llm_generated+aimeTagAnalysis+0+0.03227005526423454+3",3,"recommend_query_list","ztxxx06c0a024223920bbbeb1e0926","send_text","item_type","rec_info","display_text","rec_reason","root","relative","iwencai\u002FrecommendList0326","aigc",Array(0),"\u002F"));</script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/b929a16.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/28ccbec.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/d9802b5.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/2077034.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/1e0f8d6.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/7a5f495.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/921844b.js" defer=""></script>